Name: Telomir Pharmaceuticals, Inc. (TELO) Financial Statements
Creator: FinSpry

Telomir Pharmaceuticals Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scale:

Scroll to see more

Telomir Pharmaceuticals, Inc. income statement - Annual data in millions USD
Breakdown	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Revenue & Gross Profit
Revenue	0.00	0.00	0.00	0.00
Cost of Revenue	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	0.00	0.00
Operating Expenses
Research & Development	2.24	1.57	0.83	0.13
Selling, General & Administrative	9.64	0.60	0.02	0.01
Operating Expenses	12.24	3.94	0.85	0.14
Operating Income	-12.24	-3.94	-0.85	-0.14
Other Income/Expense
Interest Income	0.05	0.00	0.00	0.00
Interest Expense	-4.34	1.64	0.00	0.00
Other Income/Expense	-4.29	-7.49	0.00	0.00
Income
Income Before Tax	-16.53	-13.07	-0.85	-0.14
Income Tax Expense	0.00	0.00	0.00	0.00
Net Income	-16.53	-13.07	-0.85	-0.14
Net Income - Continuous Operations	-16.53	-13.07	-0.85	-0.14
Net Income - Discontinued Operations	0.00	0.00	0.00	0.00
EBITDA	0.05	-11.43	-0.85	-0.14
EBIT	-12.19	-11.43	-0.85	-0.14
Depreciation & Amortization	12.24	0.00	0.00	0.00
Earnings Per Share
Basic EPS	-1.00	-	-	-
Diluted EPS	-1.00	-	-	-
Basic Shares Outstanding	29.54	29.61	26.83	29.61
Diluted Shares Outstanding	29.54	29.61	26.83	29.61